Replimune Group (REPL) has an average rating of underweight and mean price target of $2.20, according to analysts polled by FactSet.
(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Price: $8.38, Change: $+3.70, Percent Change: +78.95%
Neurocrine Biosciences (NBIX) could see more upside from wider Crenessity use, easing insurance limits, stronger patient demand and likely commercial product beats in 2026, RBC Capital Markets said in a note Friday.RBC said its survey of 35 endocrinologists showed Crenessity still has room to grow after a strong Q1, even as some investors worry near-term demand may slow as surveyed doctors now use Crenessity in about 23% of their Congenital Adrenal Hyperplasia patients on average and expect usage to reach 37% by the end of 2026.The firm raised its 2026 Crenessity sales estimate to $750 million from $734 million, above the roughly $650 million consensus estimate, saying the target looks achievable even with more cautious growth assumptions and longer-term demand also looks strong, with doctors expecting to use Crenessity in just over half of their CAH patients within five years.Insurance approvals remain the main barrier to wider use, but RBC expects those issues to ease over time and support further adoption, according to the note.RBC kept the company's outperform rating and raised its price target to $183 from $180.Price: $157.29, Change: $+0.90, Percent Change: +0.58%
Okta (OKTA) reported a strong fiscal Q1 with outperformanceacross the board and a guidance raise, RBC Capital Markets said in a Friday note."Momentum is building for both new products and a GTM perspective with specialization and capacity increase benefits both yielding results," the report said.Based on accelerating current remaining performance obligation growth, additional upside to fiscal 2027 estimates seems likely given strong execution and positive demand signals, it said.The note also said early traction with agentic security remains encouraging and could represent a source of upside.RBC maintained its outperform rating and raised its price target to $122 from $108 on higher estimates.Price: $120.31, Change: $+25.59, Percent Change: +27.02%
Essential Utilities' (WTRG) merger with American Water Works (AWK) offers an attractive upside with a 20% total return potential, UBS said in a Friday research report.The company's standalone positives includes a steady credit profile, a low-risk and capital-intensive growth plan, and stable regulatory relations, according to the note.UBS upgraded the stock to buy from neutral and raised its price target to $43 from $41.Price: $36.91, Change: $+0.22, Percent Change: +0.60%